Patrick Ward, MD
Hematology & Oncology · Cincinnati, OHNPI 1093709297
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $15,102 of the $18,422 with a category attached, or 82.0%. It is spread thinly across 27 manufacturers, the largest accounting for just 22.6%.
Across 78 payments — averaging $236.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$4K
- Boehringer Ingelheim$3K
- Fresenius Kabi USA, LLC$2K
- Daiichi Sankyo Inc.$2K
- Amgen$2K
- Eli Lilly$2K
- plus $3K from 21 others
Across 1,152 payments — averaging $3343.12 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Amgen$1.1M
- E.r. Squibb & Sons, L.L.C.$629K
- Eli Lilly$512K
- Seagen Inc.$366K
- Genentech, Inc.$360K
- Mirati Therapeutics, Inc.$224K
- plus $621K from 12 others
What the payments were for
- Consulting fees$15,10282%
- Speaking & faculty fees$1,0005%
- Food & beverage$2,00211%
- Education$3192%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 4 | $4,163 |
| Boehringer Ingelheim | 1 | $3,010 |
| Fresenius Kabi USA, LLC | 1 | $2,200 |
| Daiichi Sankyo Inc. | 3 | $2,099 |
| Amgen | 5 | $1,913 |
| Eli Lilly | 1 | $1,875 |
| Avyxa Pharma, LLC | 1 | $1,000 |
| Johnson & Johnson | 7 | $635 |
| AbbVie | 14 | $429 |
| Genentech USA, Inc. | 4 | $243 |
| EMD Serono, Inc. | 1 | $122 |
| Novartis | 6 | $109 |
| Pfizer | 7 | $102 |
| Gilead | 5 | $98 |
| Myovant Sciences Inc. | 1 | $95 |
| AVEO Pharmaceuticals, Inc. | 3 | $85 |
| Amneal Pharmaceuticals LLC | 2 | $36 |
| Lilly USA, LLC | 2 | $35 |
| Merck | 2 | $31 |
| G1 Therapeutics, Inc. | 1 | $29 |
| E.r. Squibb & Sons, L.L.C. | 1 | $22 |
| Eisai Inc. | 1 | $20 |
| Azurity Pharmaceuticals, Inc. | 1 | $16 |
| Regeneron Healthcare Solutions, Inc. | 1 | $15 |
| Pharmacyclics LLC, An Abbvie Company | 1 | $14 |
| Incyte Corporation | 1 | $14 |
| Bayer | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$18,422 in reported general payments places this provider in the 80th percentile of 450 hematology & oncology providers in Ohio.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VerzenioAbemaciclib | 60 | $906,017 |
| ImbruvicaIbrutinib | 54 | $848,030 |
| TagrissoOsimertinib Mesylate | 40 | $653,685 |
| CalquenceAcalabrutinib Maleate | 27 | $416,204 |
| ErleadaApalutamide | 27 | $398,424 |
| RubracaRucaparib Camsylate | 12 | $177,591 |
| XtandiEnzalutamide | 12 | $172,859 |
| BrukinsaZanubrutinib | 11 | $163,913 |
| TasignaNilotinib Hcl | 11 | $103,615 |
| Abiraterone Acetate | 14 | $51,242 |
| EliquisApixaban | 40 | $23,306 |
| Imatinib Mesylate | 20 | $13,934 |
| Letrozole | 298 | $4,364 |
| Prochlorperazine Maleate | 32 | $1,322 |
| Exemestane | 19 | $1,315 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTagrisso, Calquence | $4,163 | $1,069,88967 claims |
| Lilly USA, LLCVerzenio, Olanzapine | $35 | $906,308102 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $14 | $848,03054 claims |
| Johnson & JohnsonErleada | $635 | $398,42427 claims |
| NovartisTasigna | $109 | $103,61511 claims |
| PfizerEliquis | $102 | $23,30640 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 450 hematology & oncology providers in Ohio.
Other hematology & oncology in Cincinnati
- David WaterhouseCincinnati$1.3M
- Mark AndolinaCincinnati$402K
- James EssellCincinnati$214K
- Akash MukherjeeCincinnati$132K
- Davendra SohalCincinnati$112K
- Edward FaberCincinnati$72K
- Alexander StarodubCincinnati$72K
- Brittaney Belle GordonCincinnati$53K
- Soumit BasuCincinnati$46K
- Trisha Wise-DraperCincinnati$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.